Table 2 Baseline characteristics of the study population stratified by systemic glucocorticoid use
No glucocorticoid use | Glucocorticoid use | P | |
|---|---|---|---|
(n = 302) | (n = 84) | ||
Median (IQR) | Median (IQR) | ||
Calprotectin (ng/mL) | 135.53 (97.84 – 193.46) | 176.05 (123.64 – 234.20) | <0.01 |
Neutrophil count (x 10 9 /L) | 5.88 (4.60 – 7.32) | 8.47 (6.68 – 10.20) | <0.01 |
Lymphocyte count (x 10 9 /L) | 1.92 (1.47 – 2.46) | 1.43 (1.01 – 1.78) | <0.01 |
NLR | 2.83 (2.03 – 4.57) | 5.79 (4.17 – 9.66) | <0.01 |
YKL-40 (ng/mL) | 77 (53 – 119) | 105 (55 – 140) | 0.059 |
Age (years) | 71 (64 – 75) | 70.5 (65 – 77.5) | 0.305 |
BMI | 24.22 (20.70 – 27.70) | 24.17 (20.86 – 27.69) | 0.914 |
FEV 1 % predicted | 40.20 (30.34 – 49.50) | 34.84 (27.89 – 42.57) | <0.01 |
Median (CI 95%) | Median (CI 95%) | ||
Survival time (days) | 1851 (1632 – 2109) | 1080 (680 – 1283) | <0.01 |
n (%) | n (%) | ||
Gender (male) | 148 (49) | 43 (51) | 0.723 |
CSI (>3) | 56 (19) | 20 (24) | 0.283 |
Current smoker | 121 (42) | 32 (38) | 0.744 |
Moderate COPD | 86 (28) | 18 (21) | |
Severe COPD | 150 (50) | 42 (50) | |
Very severe COPD | 66 (22) | 24 (29) | |
n (Median dose) | |||
Maintenance glucocorticoid therapy | - | 73 (10 mg/day) |